Moreover, in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-resistant and EGFR-TKI-naive NSCLC patients, a combination of c-MET inhibitors and EGFR-TKIs (EGFR inhibitors) may be considered as a promising treatment option [15]. Here, EGFR is linked to non-small cell lung carcinoma.